Release date: 2024-08-15 17:50:17 Article From: Lucius Laos Recommended: 157
Selpercatinib interferes with the growth signal of cancer cells by selectively inhibiting RET kinase. It is suitable for a variety of RET gene-related cancer types, such as medullary thyroid cancer, providing patients with new treatment options.
Patients should have a detailed understanding of the indications of the drug before choosing to be treated with Selpercatinib.
Selpercatinib is indicated for the treatment of previously treated, inoperable locally advanced or metastatic cholangiocarcinoma, particularly those where fibroblast growth factor receptor 2 (FGFR2) fusions or other FDA-approved rearrangements have been detected.
Selpercatinib is indicated for the treatment of adult patients with relapsed or refractory myeloid/lymphoid tumors (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements.
It is important for doctors and patients to know the dosage and dosage of the drug, according to the drug label:
Dose adjustment when used concomitantly with strong or moderate CYP3A inhibitors
Avoid concomitant use of strong or moderate CYP3A inhibitors with Selpercatinib. If you can't avoid it:
The dose of Selpercatinib was reduced from 13.5mg to 9mg, and the dose of Selpercatinib was reduced from 9mg to 4.5mg.
If a strong or moderate CYP3A inhibitor is discontinued, the dose of Selpercatinib should be restored to the level prior to initiation of the inhibitor after 3 plasma half-lives of the CYP3A inhibitor have been discontinued.
Adverse drug reactions that may occur during the use of Selpercatinib include, but are not limited to, the following.
Frequent vomiting can lead to dehydration and electrolyte imbalances, further aggravating the patient's discomfort. To relieve vomiting symptoms, your doctor may prescribe anti-vomiting medications and advise you to eat small, frequent meals and avoid irritating foods.
Pain in the joints may affect the patient's range of motion and daily life. To alleviate joint pain, patients can use painkillers and exercise appropriately to keep their joints flexible.
[Warm tips] Follow the advice of your doctor or pharmacist to maintain a healthy lifestyle while taking the medicine to help better manage your condition.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: